Drug Development

Qnovia secures a license for a novel peptide, D8, that kills superbugs differently. Can this university-born innovation turn the tide on antibiotic resistance?

A single IV shot to halt Parkinson's? Shape Therapeutics' radical RNA-editing therapy, now backed by The Michael J. Fox Foundation, aims to do just that.

A new study on umbilical cord allografts offers hope for chronic neck pain, but a closer look reveals the complex scientific and regulatory networks that will define its future.

Shionogi launches XOCOVA, the first oral pill to prevent COVID after exposure. With a 67% efficacy rate and a $1,400 price tag, who will it protect?

Oak Hill Bio is betting on a therapy shelved by a pharma giant. Its new trial for Angelman syndrome tests a disruptive model for rare disease innovation.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

On World Lung Cancer Day, a $400,000 investment isn't just funding research; it's backing a new generation of scientists tackling the disease's biggest challenges.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

AsymBio breaks ground on a Shanghai R&D center, integrating AI and manufacturing to slash drug development timelines. Is this the end of the CDMO handoff?

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?